Somatostatin-dopamine ligands in the treatment of pituitary adenomas. (Q37225446)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

review article

1 reference

title

Somatostatin-dopamine ligands in the treatment of pituitary adenomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

Philippe Jaquet

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

publication date

24 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

Reviews in Endocrine and Metabolic Disorders

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

83-90

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

Protein tyrosine nitration in cytokine-activated murine macrophages. Involvement of a peroxidase/nitrite pathway rather than peroxynitrite

11 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11154-008-9086-0

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors

21 January 2018

1 reference

12 December 2020

Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer

1 reference

12 December 2020

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

1 reference

12 December 2020

Dopamine D2 receptor dimer formation: evidence from ligand binding

1 reference

12 December 2020

Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline

1 reference

12 December 2020

Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

1 reference

12 December 2020

Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment

1 reference

12 December 2020

Spiro[1H-indene-1,4'-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists

1 reference

12 December 2020

Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.

1 reference

12 December 2020

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas

1 reference

12 December 2020

Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

G-protein-coupled receptor oligomerization and its potential for drug discovery

1 reference

12 December 2020

Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.

1 reference

12 December 2020

Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas.

1 reference

12 December 2020

Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis.

1 reference

12 December 2020

Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.

1 reference

12 December 2020

Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro

1 reference

12 December 2020

Dopamine D2 receptor dimers and receptor-blocking peptides

1 reference

12 December 2020

Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions

1 reference

12 December 2020

Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors

1 reference

12 December 2020

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion

1 reference

12 December 2020

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

1 reference

12 December 2020

Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology

1 reference

12 December 2020

Dopamine receptor expression and function in corticotroph pituitary tumors

1 reference

12 December 2020

Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas

1 reference

12 December 2020

Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving G(s).

1 reference

12 December 2020

Somatostatin analogs in acromegaly

1 reference

12 December 2020

Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography

1 reference

12 December 2020

Abnormal transduction mechanisms in pituitary adenomas

1 reference

12 December 2020

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.

1 reference

12 December 2020

Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy

1 reference

12 December 2020

Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.

1 reference

12 December 2020

Quantitative analysis of somatostatin receptor subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas

1 reference

12 December 2020

Dopamine D2 receptor gene expression in human adenohypophysial adenomas

1 reference

12 December 2020

Inhibitory effect of L-Dopa on GH release in acromegalic patients

1 reference

12 December 2020

A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies

1 reference

12 December 2020

Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes

1 reference

12 December 2020

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

1 reference

12 December 2020

Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

1 reference

12 December 2020

Evidence for Differential Effects of Selective Somatostatin Receptor Subtype Agonists on α-Subunit and Chromogranin A Secretion and on Cell Viability in Human Nonfunctioning Pituitary Adenomasin Vitro

1 reference

12 December 2020

Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes

1 reference

12 December 2020

Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization

1 reference

12 December 2020

Peptide receptors as molecular targets for cancer diagnosis and therapy

1 reference

12 December 2020

Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.

1 reference

12 December 2020

Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A).

1 reference

12 December 2020

Roles of G-protein-coupled receptor dimerization

1 reference

12 December 2020

Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.

1 reference

12 December 2020

Cabergoline in the treatment of acromegaly: a study in 64 patients.

1 reference

12 December 2020

Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers

1 reference

12 December 2020

Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis

1 reference

12 December 2020

Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors

1 reference

12 December 2020

Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas

1 reference

12 December 2020

The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro

1 reference

12 December 2020

The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients

1 reference

12 December 2020

The origins of diversity and specificity in g protein-coupled receptor signaling

1 reference

12 December 2020

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity

1 reference

12 December 2020

Somatostatin and its receptor family

1 reference

12 December 2020

Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation

1 reference

12 December 2020

Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth

1 reference

12 December 2020

Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells

1 reference

12 December 2020

Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.

1 reference

12 December 2020

Resistance to bromocriptine in prolactinomas

1 reference

12 December 2020

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro

1 reference

12 December 2020

Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells

1 reference

12 December 2020

The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors

1 reference

12 December 2020

Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.

1 reference

12 December 2020

Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro

1 reference

12 December 2020

The pathophysiological consequences of somatostatin receptor internalization and resistance

1 reference

12 December 2020

Global analysis of G-protein-coupled receptor signaling in human tissues

1 reference

12 December 2020

A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation

1 reference

12 December 2020

A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients

1 reference

12 December 2020

10.1007/S11154-008-9086-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18651224%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference